Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

There are no transmission terms in the subcorpus


Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 2 records in total 2
    records per page




    SARS-COV-2 infection MESHD during pregnancy, a risk factor for eclampsia MESHD eclampsia HP or neurological manifestations of COVID-19? Case report.

    Authors: Alejandro Garcia Rodriguez; Sergio Marcos Contreras; Santiago Manuel Fernandez Manovel; Jose Miguel Marcos Vidal; Fernando Diez Buron; Camino Fernandez Fernandez; Maria del Carmen Riveira Gonzalez

    doi:10.21203/rs.3.rs-40372/v1 Date: 2020-07-06 Source: ResearchSquare

    Background: There are no published cases of tonic-clonic seizures MESHD seizures HP and posterior bilateral blindness MESHD blindness HP during pregnancy and SARS-COV-2 infection MESHD. We do not just face new and unknown manifestations, but also how different patients groups are affected by SARS-Cov-2 infection MESHD, like pregnant women. COVID-19, preeclampsia HP, eclampsia MESHD eclampsia HP and posterior reversible leukoencephalopathy MESHD leukoencephalopathy HP share endothelium damage and similar pathophysiology. Case presentation: We present a case of a 35 years old pregnant woman, who comes to our hospital because of tonic-clonic seizures MESHD seizures HP at home and SARS-COV-2 infection MESHD. After Caesarean section, we initiate antihypertensive treatment with labetalol, amlodipine and captopril. Few hour after C-section, she develops blindness MESHD blindness HP with total recuperation after 72 hours, normal brain CT scan and normal CT angiography. She had normal pregnancy control and no other symptoms before tonic-clonic seizures MESHD seizures HP development. Conclusion: SARS-COV-2 infection MESHD could promote brain endothelial damage and facilitate neurological complications during pregnancy MESHD.

    BRAIN MR SPECTROSCOPIC FINDINGS IN THREE CONSECUTIVE COVID-19 PATIENTS: PRELIMINARY OBSERVATIONS

    Authors: Otto Rapalino; Alika Weerasekera; Sarah J. Moum; Katharina Eikermann-Haerter; Brian L Edlow; David Fischer; Shibani Mukerji; Pamela Schaefer,; R. Gilberto Gonzalez; Michael Lev; Eva-Maria Ratai

    doi:10.1101/2020.06.10.20122465 Date: 2020-06-16 Source: medRxiv

    Brain magnetic resonance spectroscopic imaging (MRSI) was performed in three consecutive COVID-19 patients, as part of a pilot investigation of the pathophysiological processes underlying the brain involvement by the SARS-CoV-2 infection MESHD. These included one with necrotizing leukoencephalopathy MESHD leukoencephalopathy HP, one after recent PEA cardiac arrest HP without leukoencephalopathy MESHD leukoencephalopathy HP, and one without frank encephalopathy HP or recent severe hypoxic episode. The MRSI findings were compared to those of two patients with white matter pathology not SARS-CoV2 infection MESHD related, and a control patient without clinical encephalopathy HP. The N-acetyl-aspartate reduction, choline elevation, and glutamate/glutamine elevation found in the COVID necrotizing leukoencephalopathy MESHD leukoencephalopathy HP patient and, to a lesser degree, the COVID post- cardiac arrest HP patient, follow a similar pattern as seen with the delayed post-hypoxic leukoencephalopathy MESHD leukoencephalopathy HP patient. Lactate elevation was most pronounced in the patient with COVID necrotizing leukoencephalopathy MESHD leukoencephalopathy HP.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.